Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 4 | 2025 | 191 | 1.320 |
Why?
|
| Dermatomyositis | 3 | 2023 | 21 | 0.910 |
Why?
|
| Fasciitis | 1 | 2024 | 20 | 0.890 |
Why?
|
| Myositis | 3 | 2023 | 62 | 0.890 |
Why?
|
| Arthritis, Juvenile | 4 | 2024 | 43 | 0.820 |
Why?
|
| Eosinophilia | 1 | 2024 | 101 | 0.800 |
Why?
|
| Autoantibodies | 6 | 2023 | 434 | 0.790 |
Why?
|
| Gastrointestinal Diseases | 1 | 2025 | 336 | 0.740 |
Why?
|
| Lung Diseases | 4 | 2023 | 383 | 0.720 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 11 | 0.720 |
Why?
|
| Lipodystrophy | 1 | 2021 | 33 | 0.710 |
Why?
|
| Skin Diseases | 1 | 2021 | 129 | 0.650 |
Why?
|
| Immunologic Factors | 2 | 2020 | 174 | 0.630 |
Why?
|
| Hospitalists | 1 | 2019 | 45 | 0.620 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 74 | 0.600 |
Why?
|
| Hemorrhage | 3 | 2023 | 467 | 0.590 |
Why?
|
| Skin Ulcer | 2 | 2021 | 33 | 0.570 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 70 | 0.530 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 77 | 0.530 |
Why?
|
| Rituximab | 1 | 2017 | 157 | 0.530 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 152 | 0.500 |
Why?
|
| Child | 22 | 2025 | 24374 | 0.470 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 205 | 0.460 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 770 | 0.460 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 2891 | 0.450 |
Why?
|
| Tenosynovitis | 1 | 2014 | 6 | 0.450 |
Why?
|
| Wrist Joint | 1 | 2014 | 24 | 0.440 |
Why?
|
| Ankle Joint | 1 | 2014 | 35 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 728 | 0.420 |
Why?
|
| Polyarteritis Nodosa | 1 | 2012 | 7 | 0.400 |
Why?
|
| Lupus Nephritis | 3 | 2022 | 44 | 0.390 |
Why?
|
| Vascular Diseases | 1 | 2023 | 168 | 0.380 |
Why?
|
| Adolescent | 15 | 2025 | 19279 | 0.350 |
Why?
|
| Age of Onset | 2 | 2025 | 586 | 0.330 |
Why?
|
| Polymyositis | 1 | 2018 | 7 | 0.300 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 16 | 0.290 |
Why?
|
| Acyl Coenzyme A | 1 | 2017 | 25 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 3552 | 0.270 |
Why?
|
| Female | 21 | 2025 | 66482 | 0.270 |
Why?
|
| Humans | 31 | 2025 | 124593 | 0.260 |
Why?
|
| Child, Preschool | 9 | 2024 | 14009 | 0.260 |
Why?
|
| Interferon Type I | 3 | 2021 | 107 | 0.240 |
Why?
|
| Male | 19 | 2025 | 61191 | 0.240 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2025 | 19 | 0.240 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2025 | 30 | 0.240 |
Why?
|
| Scleroderma, Localized | 1 | 2025 | 7 | 0.240 |
Why?
|
| Arthritis | 2 | 2023 | 80 | 0.230 |
Why?
|
| Pancreatitis | 1 | 2025 | 129 | 0.220 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 573 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 30 | 0.200 |
Why?
|
| Neoplasms | 1 | 2017 | 2771 | 0.200 |
Why?
|
| Glomerulonephritis | 1 | 2023 | 73 | 0.200 |
Why?
|
| Methotrexate | 1 | 2024 | 341 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 251 | 0.190 |
Why?
|
| Hemoptysis | 1 | 2021 | 22 | 0.190 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2021 | 19 | 0.180 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2021 | 13 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1111 | 0.180 |
Why?
|
| Coatomer Protein | 2 | 2023 | 30 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2021 | 36 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2023 | 480 | 0.170 |
Why?
|
| Cough | 1 | 2021 | 88 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1882 | 0.170 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 647 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 65 | 0.170 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nephrology | 1 | 2022 | 145 | 0.170 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2020 | 11 | 0.170 |
Why?
|
| Panniculitis | 1 | 2020 | 19 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2020 | 61 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2022 | 236 | 0.160 |
Why?
|
| Piperidines | 1 | 2021 | 204 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 150 | 0.160 |
Why?
|
| Kidney | 3 | 2022 | 1358 | 0.160 |
Why?
|
| Transition to Adult Care | 1 | 2021 | 119 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 144 | 0.150 |
Why?
|
| Fever | 1 | 2021 | 294 | 0.150 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 29 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2021 | 369 | 0.140 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2017 | 12 | 0.140 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 167 | 0.140 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 89 | 0.130 |
Why?
|
| Infant | 5 | 2022 | 12468 | 0.130 |
Why?
|
| Immunologic Tests | 1 | 2016 | 19 | 0.130 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2016 | 10 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2016 | 100 | 0.130 |
Why?
|
| Adult | 5 | 2024 | 29438 | 0.120 |
Why?
|
| Mutation | 2 | 2020 | 5825 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 670 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2020 | 520 | 0.120 |
Why?
|
| Aftercare | 1 | 2016 | 147 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3424 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 309 | 0.110 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 47 | 0.110 |
Why?
|
| Tropomyosin | 1 | 2023 | 26 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1198 | 0.100 |
Why?
|
| HIV Infections | 1 | 2025 | 1892 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2017 | 1387 | 0.100 |
Why?
|
| Gangrene | 1 | 2012 | 26 | 0.100 |
Why?
|
| Cytoskeletal Proteins | 1 | 2023 | 267 | 0.100 |
Why?
|
| Extremities | 1 | 2012 | 82 | 0.090 |
Why?
|
| Necrosis | 1 | 2012 | 208 | 0.090 |
Why?
|
| Cerebrum | 1 | 2010 | 33 | 0.090 |
Why?
|
| Contrast Media | 1 | 2014 | 471 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2023 | 521 | 0.080 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2010 | 14 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 4256 | 0.080 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2010 | 23 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3694 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 1110 | 0.080 |
Why?
|
| Young Adult | 3 | 2022 | 9014 | 0.080 |
Why?
|
| Aortitis | 1 | 2008 | 6 | 0.070 |
Why?
|
| Syndrome | 2 | 2023 | 1119 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3153 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2010 | 299 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2017 | 6135 | 0.070 |
Why?
|
| Cerebellum | 1 | 2010 | 413 | 0.070 |
Why?
|
| Logistic Models | 2 | 2017 | 1805 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2008 | 283 | 0.060 |
Why?
|
| Malawi | 1 | 2025 | 397 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 28 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2024 | 120 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2024 | 91 | 0.050 |
Why?
|
| Biopsy | 1 | 2007 | 1237 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 325 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 208 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 217 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2022 | 78 | 0.050 |
Why?
|
| Microscopic Polyangiitis | 1 | 2021 | 14 | 0.050 |
Why?
|
| Myeloblastin | 1 | 2021 | 18 | 0.050 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2021 | 21 | 0.050 |
Why?
|
| Peroxidase | 1 | 2021 | 62 | 0.050 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2021 | 38 | 0.050 |
Why?
|
| United States | 1 | 2016 | 10887 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 431 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 471 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2021 | 77 | 0.040 |
Why?
|
| North America | 1 | 2021 | 240 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16314 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 4795 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2021 | 202 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1428 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2013 | 1185 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 316 | 0.040 |
Why?
|
| Biomarkers | 1 | 2017 | 3063 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 61 | 0.040 |
Why?
|
| Brain | 1 | 2010 | 2983 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2091 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 115 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 1998 | 70 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1420 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 120 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 180 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1998 | 106 | 0.030 |
Why?
|
| Gait | 1 | 1998 | 145 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 263 | 0.030 |
Why?
|
| Vision Disorders | 1 | 1998 | 211 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 672 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1290 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 607 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 796 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2047 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1491 | 0.030 |
Why?
|
| Family | 1 | 2018 | 562 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2015 | 45 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 381 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5145 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 3090 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1706 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2749 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2816 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2017 | 12322 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3441 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1431 | 0.020 |
Why?
|
| Atrophy | 1 | 2010 | 228 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 711 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3583 | 0.020 |
Why?
|
| Infliximab | 1 | 2008 | 67 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 160 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 7 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 253 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 10270 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 547 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 250 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 287 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 721 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8189 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 418 | 0.010 |
Why?
|
| Neutrophils | 1 | 2007 | 381 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1018 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 6292 | 0.010 |
Why?
|